Clinical trial results:
AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF N-ACETYL-GED-0507-34-LEVO GEL 5% IN PATIENTS WITH FACIAL ACNE

Summary

EudraCT number	2017-003796-58
Trial protocol	IT
Global end of trial date	27 June 2019

Results information

Result version number	v1 (current)
This version publication date	14 July 2021
First version publication date	14 July 2021
Summary attachment (see zip file)	SUMMARY REPORT (GED-0507-ACN-02-17 CSR - SUMMARY FINAL 11.06.2020.pdf)

Trial information

Trial identification

Sponsor protocol code	NAC-GED-0507-ACN-02-17

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	U1111-1203-0648

Notes:

Sponsors

Sponsor organisation name	PPM SERVICES SA
Sponsor organisation address	Viale Serfontana 10, Morbio Inferiore, Switzerland, 6834
Public contact	MEDICAL DEPARTMENT, PPM SERVICES SA, 0041 916969710, sbellinvia@ppmservices.ch
Scientific contact	MEDICAL DEPARTMENT, PPM SERVICES SA, 0041 916969710, sbellinvia@ppmservices.ch

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 June 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	27 June 2019
Global end of trial reached?	Yes
Global end of trial date	27 June 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Local and systemic safety and tolerability of N-Acetyl-GED-0507-34-Levo after 12 weeks repeated daily exposures to 5% gel in patients affected by facial acne vulgaris.
Plasmatic concentration of N-Acetyl-GED-0507-34-Levo after 12 weeks repeated daily exposures to the gel containing 5% of active principle

Protection of trial subjects:

The original protocol version 1.0 of 02 October 2017 was submitted both to the Italian Regulatory Agency (AIFA) and competent Ethics Committee (IRCCS Istituti Fisioterapici Ospitalieri di Roma and received a favourable single opinion on 24 October 2017 and the authorization from AIFA on 13 December 2017, with favourable opinion by Istituto Superiore di Sanità (ISS) released on 24 November 2017.
This phase I trial was conducted in the unit Centro Studi Early Phase (CSEP) of the IRCCS IFO - Istituti Fisioterapici Ospitalieri in Roma, accredited as per Determina AIFA 809/2015 to conduct phase I trials.
Having obtained the favourable opinion from the competent IEC (IRCCS Istituti Fisioterapici Ospitalieri di Roma) and following the approval of the Competent Authorities (CAs) with favourable opinion by Istituto Superiore di Sanità (ISS), site was initiated after AIFA inspection on CSEP and following authorization to conduct phase I studies, in September 2018.
This clinical trial (Protocol no. NAC-GED-0507-ACN-02-17 Eudract Number: 2017-003796-58) was conducted in compliance with specific regulatory requirements of the Italian Ministry of Health, including D.lgs 24 June 2003 no. 211, DPR 21 September 2001 no. 439, DM 26 April 2002, DM 21 December 2007, DM 13 September 2012, Determina AIFA 07 January 2013, Determina AIFA 809/2015.
This trial was conducted in compliance with the most recent version of the Declaration of Helsinki (Fortaleza, Brazil, October 2013), the most recent version of the Good Clinical Practice (GCP), and all applicable regulatory requirements (European Directive 2001/20/EC, 04 April 2001), and Italian Laws (D.lgs no. 211, 24 June 2003 and all applicable regulations).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 October 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Italy: 25
Worldwide total number of subjects	25
EEA total number of subjects	25

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	10
Adults (18-64 years)	15
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study initiation date: 09 October 2018 (first patient enrolled)
Study completion date: 27 June 2019 (last visit of the last patient)

Pre-assignment

Screening details:

A total of 25 patients have been recruited in the study:
• 10 Patients with facial acne vulgaris with IGA score = 2 (mild)
• 10 Patients with facial acne vulgaris with IGA score = 3 (moderate)
• 5 Patients with facial acne vulgaris with IGA score = 4 (severe)

Pre-assignment period milestones

Number of subjects started	25
Number of subjects completed	25

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

The study was open label

Arms

Arm title	SIngle arm (open label study)

Arm description:

N-ACETYL-GED-0507-34-LEVO GEL 5%

Arm type	Experimental
Investigational medicinal product name	N-ACETYL-GED-0507-34-LEVO GEL 5%
Investigational medicinal product code	N-ACETYL-GED-0507-34-LEVO GEL 5%
Other name	N-ACETYL-GED-0507-34-LEVO GEL 5%
Pharmaceutical forms	Gel
Routes of administration	Topical

Dosage and administration details:

N-ACETYL-GED-0507-34-LEVO GEL 5% daily application for 12 weeks

Number of subjects in period 1	SIngle arm (open label study)
Started	25
Completed	25

Baseline characteristics

Reporting groups	
Reporting group title	Overall trial
Reporting group description:	
All subjects randomized	

Reporting group values	Overall trial	Total	
Number of subjects	25	25	
Age categorical			
The age ranged from 12.0 to 29.0 years (19.2 ± 4.27) with 15 adults (60.0%) and 10 minors (40.0%).			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	10	10	
Adults (18-64 years)	15	15	
From 65-84 years	0	0	
85 years and over	0	0	
Minor	0	0	
Adults	0	0	
Age continuous			
The age ranged from 12.0 to 29.0 years (19.2 ± 4.27) with 15 adults (60.0%) and 10 minors (40.0%).			
Units: years			
median	18		
standard deviation	± 4.27	-	
Gender categorical			
As per protocol, females were enrolled only if adults (≥ 18 years old).			
Units: Subjects			
Female	12	12	
Male	13	13	
IGA scores			
Investigator Global Assessment			
Units: Subjects			
Mild	10	10	
Moderate	10	10	
Severe	5	5	

Subject analysis sets	
Subject analysis set title	Safety population
Subject analysis set type	Safety analysis
Subject analysis set description:	
Safety population: subjects who took at least one dose of investigational product and had at least one post-dose safety assessment.	

Reporting group values	Safety population		
Number of subjects	25		
Age categorical			
The age ranged from 12.0 to 29.0 years (19.2 ± 4.27) with 15 adults (60.0%) and 10 minors (40.0%).			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	10		
Adults (18-64 years)	15		
From 65-84 years	0		
85 years and over	0		
Minor	0		
Adults	0		
Age continuous			
The age ranged from 12.0 to 29.0 years (19.2 ± 4.27) with 15 adults (60.0%) and 10 minors (40.0%).			
Units: years			
median	18		
standard deviation	± 4.27		
Gender categorical			
As per protocol, females were enrolled only if adults (≥ 18 years old).			
Units: Subjects			
Female	12		
Male	13		
IGA scores			
Investigator Global Assessment			
Units: Subjects			
Mild	10		
Moderate	10		
Severe	5		

End points

End points reporting groups

Reporting group title	SIngle arm (open label study)

Reporting group description:

N-ACETYL-GED-0507-34-LEVO GEL 5%

Subject analysis set title	Safety population
Subject analysis set type	Safety analysis

Subject analysis set description:

Safety population: subjects who took at least one dose of investigational product and had at least one post-dose safety assessment.

Primary: Safety endpoint

End point title	Safety endpoint[1]

End point description:

The primary objective of the study was to determine local and systemic safety and tolerability of N-Acetyl-GED-0507-34-Levo after 12 weeks repeated daily exposures to 5% gel in patients with facial acne.

End point type	Primary

End point timeframe:

12 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: DESCRIPTIVE STATISTIC (FREQUENCY TABLES) IS PROVIDED

End point values	SIngle arm (open label study)	Safety population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	25	25		
Units: TEAEs related to study drug	3	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Overall

Adverse event reporting additional description:

30 adverse events, which occurred in 19 subjects (76.0%), were registered during the study. In detail, 5 events in 3 subjects with severe IGA, 12 events in 8 subjects with moderate IGA, and 13 events in 8 subjects with mild IGA. All of them were resolved. No SAEs were reported during the study.No AE lead to permanent discontinuation of treatment

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23

Reporting groups

Reporting group title	Summary AE

Reporting group description:

Characteristics and description of adverse events occurred during the study are listed in Table XIII.
Thirty (30) adverse events, which occurred in 19 subjects (76.0%), were registered during the study. In detail, 5 events in 3 subjects with severe IGA, 12 events in 8 subjects with moderate IGA, and 13 events in 8 subjects with mild IGA. All of them were resolved.
As about the severity of the event, 19 (63.3%) were considered of mild intensity, 9 (30.0%) moderate, and 2 (6.7%) severe. Three (3) events occurred in 2 patients with mild IGA were judged possible related to study treatment.
No SAEs were reported during the study. No AE lead to permanent discontinuation of study treatment.

Serious adverse events	Summary AE		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Summary AE		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 25 (76.00%)		
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 25 (8.00%)		
occurrences (all)	2		
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3		
Gastrointestinal disorders Gastroenteritis subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2		
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2		
Skin and subcutaneous tissue disorders Application site drynes subjects affected / exposed occurrences (all)	6 / 25 (24.00%) 6		
Infections and infestations Influenza subjects affected / exposed occurrences (all)	4 / 25 (16.00%) 4		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

in the interpretation of the results the main limits of this study must be considered: a) open study design; b) absence of control group; c) relatively small size of the three study groups; d) study duration limited to 12 weeks.

Notes: